All In Biotech

Drug Trial Radar · NCT05352919

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 864 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

864

Planned (sponsor's estimate)

Start

Jun 10, 2022

Primary completion

May 3, 2032

Study completion May 3, 2032

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on adults who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. This is an extension study of 230LE303 and 230LE304 (TOPAZ-1 and TOPAZ-2). It will include participants who completed the treatment periods of either one of those parent studies. The main goal of the study is to learn more about the long-term safety of litifilimab in adults. The main question researchers want to answer is: \- How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug. Researchers will also learn about: * The effect of litifilimab on controlling symptoms of SLE and lowering its activity. * How participants' immune systems respond to litifilimab. * The effect of litifilimab on the quality of life of participants. The study will be done as follows: * This study begins when the participant has finished 1 of the parent studies (either 230LE303 or 230LE304). * Participants who were getting either a high or low dose of litifilimab in either parent study will continue getting the same doses. * Participants who were getting the placebo in the parent studies will be randomized to get either a high or low dose of litifilimab. * Neither the researchers nor the participants will know which doses of litifilimab the participants are getting. * All participants will get litifilimab as injections under the skin once every 4 weeks. The treatment period will last up to 260 weeks. Participants may continue to take their standard of care medications. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 73 study visits. At these visits, the study doctor will do tests to check the participants' overall health, including the status of their SLE symptoms. They will also measure the participants' height, weight, and vital signs and collect blood and urine samples. Participants will also complete questionnaires or answer questions about how they are feeling and about their daily lives. * Each participant will be in the study for up to 284 weeks. Optional Substudy: * Some participants may be invited to join an optional "substudy" after being in the main study for at least 4 months. * This substudy will test a new injector device for delivering litifilimab. The injector device is an automatic device that delivers the full dose in 1 injection without needing to push a plunger. * Researchers will learn more about the safety of the injector device and how the body reacts to it. This will be compared to the current prefilled syringe method. * The substudy will last up to 3 months and will include about 120 participants.

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • LitifilimabDrug

    Administered as specified in the treatment arm.

  • Litifilimab-matching placeboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Week 284
  2. Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to Week 284

Locations

214 sites in 28 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona

  • Wallace Rheumatic Study Center

    Beverly Hills, California

  • Care Access Research - Huntington Beach

    Huntington Beach, California

  • Providence Facey Medical Foundation

    Mission Hills, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • University of Colorado Denver

    Aurora, Colorado

  • Georgetown University Hospital-Medstar

    Washington D.C., District of Columbia

  • Arthritis & Rheumatic Disease Specialties

    Aventura, Florida

  • Highlands Research Institute

    Avon Park, Florida

  • Clinical Research of West Florida - Corporate

    Clearwater, Florida

  • GNP Research at Mark Jaffe, MD

    Cooper City, Florida

  • Omega Research Consultants

    DeBary, Florida

  • Life Clinical Trials

    Margate, Florida

  • HMD Research, LLC

    Orlando, Florida

  • Clinical Research of West Florida, Inc.

    Tampa, Florida

  • AdventHealth Medical Group

    Tampa, Florida

  • Arthritis Center of North Georgia

    Gainesville, Georgia

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • AA MRC LLC Ahmed Arif Medical Research Center

    Flint, Michigan

  • Precision Comprehensive Clinical Research Solutions

    Rochester Hills, Michigan

  • Saint Louis Rheumatology

    St Louis, Missouri

  • NYU Langone Brooklyn

    Brooklyn, New York

  • DJL Clinical Research, PLLC

    Charlotte, North Carolina

  • Onyx Clinical Research, LLC

    Salisbury, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Paramount Medical Research & Consulting, LLC

    Middleburg Heights, Ohio

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Ramesh C Gupta, MD

    Memphis, Tennessee

  • Arthritis & Rheumatology Research Institute

    Allen, Texas

  • Tekton Research - PARENT

    Austin, Texas

  • Accurate Clinical Research

    Baytown, Texas

  • Precision Comprehensive Clinical Research Solution

    Colleyville, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • Accurate Clinical Research, Inc.

    Humble, Texas

  • R and H Clinical Research

    Katy, Texas

  • Sun Research Institute, LLC

    San Antonio, Texas

  • Advanced Rheumatology of Houston

    The Woodlands, Texas

  • Swedish Medical Center

    Seattle, Washington

  • Hospital Italiano de La Plata

    Buenos Aires, Argentina

  • Instituto de Investigaciones Clinicas Quilmes

    Buenos Aires, Argentina

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.